IMC Chicago’s TG Therapeutics TGTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$757K Sell
22,800
-23,300
-51% -$694K ﹤0.01% 3566
2025
Q4
$1.37M Sell
46,100
-6,200
-12% -$202K ﹤0.01% 2731
2025
Q3
$1.89M Buy
52,300
+3,600
+7% +$119K ﹤0.01% 2268
2025
Q2
$1.75M Sell
48,700
-25,700
-35% -$957K ﹤0.01% 2101
2025
Q1
$2.93M Sell
74,400
-9,400
-11% -$316K ﹤0.01% 1542
2024
Q4
$2.52M Buy
+83,800
New +$2.4M ﹤0.01% 1688
2024
Q2
Sell
-19,100
Closed -$291K 2795
2024
Q1
$291K Buy
19,100
+2,100
+12% +$33.5K ﹤0.01% 2249
2023
Q4
$290K Buy
+17,000
New +$198K ﹤0.01% 1745

Other funds holding TGTX

IMC Chicago's TGTX Position: Q4 2025 in Review

IMC Chicago sold out of TG Therapeutics (TGTX) in Q4 2025, closing a stake of 22,903 shares — an estimated $748K sold.

IMC Chicago first reported a position in TGTX in Q4 2023 and held it in 4 quarters. The position peaked at $1M in Q2 2025. 351 funds tracked by Wall St. Rank hold TGTX as of Q4 2025.

  • IMC Chicago reported no remaining TG Therapeutics position as of Q4 2025 after selling out during the quarter.
  • IMC Chicago sold 22,903 TG Therapeutics shares in Q4 2025, an estimated $748K.
  • IMC Chicago first reported a position in TG Therapeutics in Q4 2023 and held it in 4 quarters.
  • IMC Chicago's TG Therapeutics position peaked at $1M in Q2 2025.
  • 351 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2025.

Based on IMC Chicago's 13F filing for Q4 2025, filed 29 Jan 2026.